Cerulean Pharma (CERU) Tops Q2 EPS by 6c

Cerulean Pharma (NASDAQ: CERU) reported Q2 EPS of ($0.37), $0.06 better than the analyst estimate of ($0.43).

For earnings history and earnings-related data on Cerulean Pharma (CERU) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• OceanaGold to acquire Ausgold in a deal valued at A$776M
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49